{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:57Z","timestamp":1792788537148,"version":"4.5.0"},"reference-count":21,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ISCIII","award":["ISCIII PI23\/01518"],"award-info":[{"award-number":["ISCIII PI23\/01518"]}]},{"name":"IDIPHISA","award":["ISCIII PI23\/01518"],"award-info":[{"award-number":["ISCIII PI23\/01518"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: Sodium\u2013glucose co-transporter 2 inhibitors (SGLT2is) increase uric acid excretion. The intensity of uricosuria is linked to glycosuria. (2) Methods: We aim to analyze the effect of SGLT2 inhibitors on urinary fractional excretion (FE) of uric acid and glucose in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in a single-center retrospective study with patients with T2DM and CKD who started on treatment with SGLT2is. Patients on renal replacement therapy or with glucagon-like peptide-1 (GLP1) analogs were excluded. Subgroup analysis was performed according to the estimated glomerular filtration rate (eGFR), the SGLT2i molecule, the main comorbidities, and concomitant treatment. As a secondary objective, the study analyzed the effect of SGLT2 inhibitors on uricemia levels. (3) Results: Seventy-three patients were analyzed, with a mean follow-up of 1.2 years. Uric acid and glucose FE significantly increased after the initiation of SGLT2is. This increase remained stable during the follow-up without differences among eGFR groups. No significant reduction in uricemia was observed. However, a trend towards a decrease was observed. (4) Conclusion: The use of SGLT2is in patients with CKD and T2DM is associated with an increase in uric acid FE, which maintains stability irrespective of glomerular filtration loss at least during 24 months of follow-up.<\/jats:p>","DOI":"10.3390\/jcm13051360","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T11:52:55Z","timestamp":1709034775000},"page":"1360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9796-2988","authenticated-orcid":false,"given":"Paula","family":"S\u00e1nchez-Briales","sequence":"first","affiliation":[{"name":"Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigaci\u00f3n Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Marques Vidas","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigaci\u00f3n Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, Spain"},{"name":"Medicine Department, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4332-5759","authenticated-orcid":false,"given":"Paula","family":"L\u00f3pez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigaci\u00f3n Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"L\u00f3pez-Ill\u00e1zquez","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigaci\u00f3n Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Mart\u00edn-Testillano","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigaci\u00f3n Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Vedat-Ali","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigaci\u00f3n Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-1385","authenticated-orcid":false,"given":"Jose","family":"Portol\u00e9s","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigaci\u00f3n Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, Spain"},{"name":"Medicine Department, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"ref_1","unstructured":"Goicoechea Diezandino, M. (2023, November 15). \u00c1cido \u00darico y Enfermedad Renal Cr\u00f3nica. Nefrol al D\u00eda [Internet]. Available online: https:\/\/www.nefrologiaaldia.org\/200."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Takata, T., and Isomoto, H. (2021). Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: Renoprotective mechanisms beyond glycemic control. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094374"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/diabetology4030022","article-title":"Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms","volume":"4","year":"2023","journal-title":"Diabetology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41371-018-0134-2","article-title":"Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"33","author":"Zhao","year":"2019","journal-title":"J. Hum. Hypertens."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/jcph.1970","article-title":"Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus","volume":"62","author":"Chino","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20406223221083509","article-title":"Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: A systematic review and meta-regression of 43 randomized controlled trials","volume":"13","author":"Yip","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7520632","DOI":"10.1155\/2022\/7520632","article-title":"Impacts of Sodium\/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis","volume":"2022","author":"Akbari","year":"2022","journal-title":"J. Diabetes Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: Role of luminal glucose, GLUT9, and URAT1","volume":"316","author":"Novikov","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"R189","DOI":"10.1186\/ar4020","article-title":"Fractional clearance of urate: Validation of measurement in spot-urine samples in healthy subjects and gouty patients","volume":"14","author":"Kannangara","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Luo, Q., Xia, X., Li, B., Lin, Z., Yu, X., and Huang, F. (2019). Serum uric acid and cardiovascular mortality in chronic kidney disease: A meta-analysis. BMC Nephrol., 20.","DOI":"10.1186\/s12882-018-1143-7"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gherghina, M.E., Peride, I., Tiglis, M., Neagu, T.P., Niculae, A., and Checherita, I.A. (2022). Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063188"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of Allopurinol on the Progression of Chronic Kidney Disease","volume":"382","author":"Badve","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1038\/s41598-023-30902-7","article-title":"Longitudinal uric acid has nonlinear association with kidney failure and mortality in chronic kidney disease","volume":"13","author":"Combe","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_20","unstructured":"(2023, June 30). KDIGO 2023 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Public Review Draft. Available online: https:\/\/kdigo.org\/guidelines\/ckd-evaluation-and-management\/."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Assimacopoulos-Jeannet, F., Cusin, I., Greco-Perotto, R., Terrettaz, J., Rohner-Jeanrenaud, F., Zarjevski, N., and Jeanrenaud, B. (1991). Glucose transporters: Structure, function, and regulation. Biochimie, 73.","DOI":"10.1016\/0300-9084(91)90076-D"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/5\/1360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:05:56Z","timestamp":1760105156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/5\/1360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13051360"],"URL":"https:\/\/doi.org\/10.3390\/jcm13051360","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]}}}